Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Hyperspectral Imaging for Prediction of Preeclampsia

Systematic Evaluation of Hyperspectral Analysis as a Predictive Marker of Preeclampsia

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Preeclampsia is a hypertensive pregnancy disorder that can quickly lead to serious, potentially life-threatening outcomes for both the mother and the fetus. Typical features of preeclampsia are by endothelial and microvascular dysfunctionsNotably, such impairments in endothelial function may precede preeclampsia diagnosis and canpersist for years postpartum. In clinical practice, however, no predictive methods have yet been established that specifically reflect endothelial dysfunction in the context of preeclampsia. Hyperspectral imaging represents a new and non-invasive imaging modality that allows contact-free visualization of peripheral microcirculatory dynamics and tissue perfusion. Despite its growing use in other medical fields, this technology has not yet been systematically studied to determine its predictive potential in preeclampsia. The HIPPA project (Systematic Evaluation of Hyperspectral Analysis for Prediction of Preeclampsia) is a prospective observational study to evaluate the applicability of hyperspectral imaging as a new tool for prediction of preeclampsia.

Who May Be Eligible (Plain English)

Who May Qualify: - singleton pregnancies - age ≥ 18 years - patient's ability to provide consent - written willing to sign a consent form - women scheduled for a routine ultrasound scan in first or second trimester Who Should NOT Join This Trial: - lack of consent - language barrier - severe fetal chromosomal/genetic/structural anomalies known at study enrollment - smoking in the last two hours before measurement - diagnosis of preeclampsia at study enrollment Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * singleton pregnancies * age ≥ 18 years * patient's ability to provide consent * written informed consent * women scheduled for a routine ultrasound scan in first or second trimester Exclusion Criteria: * lack of consent * language barrier * severe fetal chromosomal/genetic/structural anomalies known at study enrollment * smoking in the last two hours before measurement * diagnosis of preeclampsia at study enrollment

Locations (1)

Heidelberg University Hospital, Department of Gynecology and Obstetrics
Heidelberg, Germany